November 5, 2026

Q3 2026 results

Clinical trial appendix



Disclosures

Certain statements contained in this presentation and in any accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include statements regarding BeOne's research, discovery, pre-clinical and clinical programs and plans.

Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne's ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeOne's most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC"), as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the SEC.

All information in this presentation is as of the date of this presentation, and BeOne undertakes no duty to update such information unless required by law.

BeOne portfolio and pipeline snapshot

As of: October 22, 2026

40+
Clinical and commercial -stage assets

80+
Approvals for BRUKINSA® (zanubrutinib) **in countries globally**

50+
Approvals for TEVIMBRA® (tislelizumab) **in countries globally**

BEQALZI™ (sonrotoclax)
Approved in U.S. for R/R MCL and in China for R/R MCL and R/R CLL

200+
Total clinical trials conducted

35,000+
Patients enrolled in clinical trials globally*

Across three therapy areas:

Hematology



Solid Tumor



Inflammation and Immunology



* Including IITs

Project movements since Q2 2026 update

As of: October 22, 2026

New to Phase I/Ib

BG-T0920-101[1]
BAFFR x CD22 x CD3 tsAb
B-cell malignancies

BG-T0050-101[1]
CD19 x CD20 x CD3 tsAb
B-cell malignancies

BG-85738-101
RAS(ON)i
GI and lung cancers

BG-92505-101[1]
KEAP1 Activator
Lung and GI cancers

BON-106-101[1]
Target not disclosed
Lung and GI cancers

BON-C1393-101[1]
B7-H3 x ITGB6 bsADC
Lung and GI cancers

New to Phase II

BGB-A317-216
Tislelizumab PD-1 mAb
1L ESCC (Q2W/Q4W) (JP)

BGB-B2033-201[1]
GPC3 x 4-1BB bsAb
2L+ HCC

New to pivotal trial

BG-C9074-301
B7-H4 ADC
1L Maintenance OC

BGB-B2033-301[1]
GPC3 x 4-1BB bsAb
2L+ HCC

Tarlatamab DeLLphi-315
DLL3 x CD3 BiTE® molecule
2L ES-SCLC (SubQ)

Accepted submission

Select markets
(AUS, U.S., BR, CA, CN, EU, JP, UK)

BGB-3111-306
Zanubrutinib BTKi
TN MCL (U.S.)

BGB-3111-306
Zanubrutinib BTKi
TN MCL (CN)

BGB-11417-201
Sonrotoclax BCL2i
R/R MCL(BR)

ZWI-ZW25-301
Tislelizumab PD-1 mAb
1L HER2+ GEA (CA)

Approved

Select markets
(AUS, U.S., BR, CA, CN, EU, JP, UK)

ZWI-ZW25-301
Tislelizumab PD-1 mAb
1L HER2+ GEA (U.S.)

BGB-A317-309
Tislelizumab PD-1 mAb
1L NPC (JP)

Removed from Phase I

BG-C137-101
FGFR2b ADC
GI and lung cancers

Removed from Phase II

Removed from Phase III

BR = Brazil; CA = Canada; CN = China; JP = Japan; U.S. = United States

[1] Trial is listed on CT.gov but may not have any subjects enrolled

A leader in Hematology

As of: October 22, 2026

	Phase 1	Phase 2	Phase 3	Approved[1]
AML/MDS, Multiple Myeloma, other Heme	**BG-75202-102** **KAT6A/Bi** Myeloid malignancies **BGB-11417-103** **Sonrotoclax BCL2i** MDS **BGB-11417-105** **Sonrotoclax BCL2i** R/R Multiple Myeloma t(11;14)	**BLINCYTO®[2]** **CD19 x CD3 BiTE® molecule** R/R and MRD+ B-ALL (subq) **BGB-11417-103** **Sonrotoclax BCL2i** AML		
B-cell	**BG-T0050-101[3]** **CD19xCD20xCD3 tsAb** B-cell malig. **BG-T0920-101[3]** **BAFFRxCD22xCD3 tsAb** B-cell malig. **BGB-11417-101** **Sonrotoclax BCL2i** Mono and combo w/zanu **BGB-16673-101** **Tacabrutideg BTK CDAC** B-cell malig. **BGB-16673-102** **Tacabrutideg BTK CDAC** B-cell malig. (CN) **BGB-16673-104** **Tacabrutideg BTK CDAC** B-cell malig. combos	**BGB-3111-304** **Zanubrutinib BTKi** TN CLL Ven combo **BGB-11417-203** **Sonrotoclax BCL2i** R/R WM **BGB-11417-108** **Sonrotoclax BCL2i** B-cell malig. dose ramp-up **BGB-11417-204** **Sonrotoclax BCL2i** TN CLL **BGB-16673-101/102** **Tacabrutideg BTK CDAC** R/R CLL and R/R WM (exp.) **BGB-16673-302** **Tacabrutideg BTK CDAC** R/R CLL	**BGB-3111-306** **Zanubrutinib BTKi** TN MCL **BGB-3111-308** **Zanubrutinib BTKi** R/R MZL, R/R FL **BGB-3111-LTE1** **Zanubrutinib BTKi** B-cell malignancies **BGB-11417-301** **Sonrotoclax BCL2i** TN CLL + zanu **BGB-11417-302** **Sonrotoclax BCL2i** R/R MCL **BGB-11417-303** **Sonrotoclax BCL2i** R/R CLL/SLL **BGB-11417-304** **Sonrotoclax BCL2i** TN CLL + zanu vs. AV **BGB-16673-303** **Tacabrutideg BTK CDAC** R/R CLL (CN) **BGB-16673-304** **Tacabrutideg BTK CDAC** R/R CLL vs. pirtobrutinib	**BGB-3111-114** **Zanubrutinib BTKi** Tablet formulation **BGB-3111-206** **Zanubrutinib BTKi** R/R MCL[4] **BGB-3111-212** **Zanubrutinib BTKi** R/R FL[4] **BGB-3111-214** **Zanubrutinib BTKi** R/R MZL[4] **BGB-3111-302** **Zanubrutinib BTKi** TN and R/R WM **BGB-3111-304** **Zanubrutinib BTKi** TN CLL/SLL **BGB-3111-305** **Zanubrutinib BTKi** R/R CLL/SLL **BGB-11417-201** **Sonrotoclax BCL2i** R/R MCL[4] **BGB-11417-202** **Sonrotoclax BCL2i** R/R CLL (CN)[4]

[1] Approved in at least one major market, such as U.S., CN, EU, and/or JP
[2] Amgen collaboration
[3] Trial is listed on CT.gov but may not have any subjects enrolled
[4] Conditional approval
Studies in "close-out" status excluded
Refer to glossary abbreviations
Blincyto® 20190359 (post approval commitment) is not included in this view

Building leadership in solid tumors with innovative new molecular entities

As of: October 22, 2026

	Phase 1	Phase 2	Phase 3	Approved[1]
Breast/ Gynecologic cancers	**BG-C9074-101[2]** **B7-H4 ADC** Breast (other ST) **BGB-43395-101** **CDK4i** Breast (other ST) **BGB-21447-102** **BCL2i** Breast **BGB-B455-101** **Claudin 6 x CD3 bsAb** Gyn (other ST) **BG-75098-101** **CDK2 CDAC** Breast and Gyn. **BG-75202-101** **KAT6A/Bi** Breast		**BGB-43395-302** **CDK4i** 1L HR+/HER2- BC **BG-C9074-301[2]** **B7-H4 ADC** 1L Maintenance OC	
Gastro-intestinal	**BGB-26808-101** **HPK1i** GI **BG-85738-101** **RAS(ON)i** GI and Lung **BGB-B2033-101** **GPC3 x 4-1BB bsAb** GI and Lung	**BGB-B2033-101** **GPC3 x 4-1BB bsAb** 3L+ HCC **BGB-B2033-201[5]** **GPC3 x 4-1BB bsAb** 2L+ HCC	**BGB-B2033-301[5]** **GPC3 x 4-1BB bsAb** 2L+ HCC	**Tarlatamab[3] DeLLphi-304** **DLL3 x CD3 BiTE® molecule** 2L SCLC (Global)
Lung	**BG-C0979-101** **ADAM9 ADC** Solid tumors **BG-C477-101** **CEA ADC** GI and Lung **BG-T187-101** **EGFR x MET x MET tsAb** Lung and GI **Tarlatamab[3] DeLLphi-308** **DLL3 x CD3 BiTE® molecule** 2L+ SCLC (SubQ) (Global) **Tarlatamab[3] DeLLphi-310** **DLL3 x CD3 BiTE® molecule** 2L+ SCLC (+B7-H3) (Global) **BON-110-101[4]** **PD-1 x VEGFAxCTLA4 tsAb** Solid tumors **BG-C0902-101** **EGFR x MET x MET tsADC** Lung and GI **BG-92505-101[5]** **KEAP1 Activator** Lung and GI **BON-106-101[5]** *Target not disclosed* Lung and GI **BGB-58067-101** **MTA-coop. PRMT5i** Lung and GI **BON-C1393-101[5]** **B7-H3 x ITGB6 bsADC** Lung and GI	**Tarlatamab[3] DeLLphi-309** **DLL3 x CD3 BiTE®molecule** 2L SCLC (Alt dosing) (Global)	**Tarlatamab[3] DeLLphi-305** **DLL3 x CD3 BiTE® molecule** 1L ES-SCLC Maintenance. (Global) **Tarlatamab[3] DeLLphi-306** **DLL3 x CD3 BiTE®molecule** LS-SCLC (Global) **Tarlatamab[3] DeLLphi-312** **DLL3 x CD3 BiTE® molecule** 1L ES-SCLC Induction. + Maint. (Global) **Tarlatamab[3] DeLLphi-315** **DLL3 x CD3 BiTE® molecule** 2L ES-SCLC SubQ (Global)	**Tarlatamab[3] DeLLphi-307** **DLL3 x CD3 BiTE® molecule** 3L+ SCLC (CN)[6]
Other	**Xaluritamig[3]** **AMG 509 20180146** **STEAP1 x CD3 BiTE® molecule** mCRPC (Global)			

[1] Approved in at least one major market, such as U.S., CN, EU, and/or JP
[2] DualityBio collaboration
[3] Amgen collaboration
[4] Huahui Health collaboration, BON-110 also known as HH-160
[5] Trial is listed on CT.gov but may not have any subjects enrolled
[6] Conditional approval
Studies in "close-out" status excluded
Refer to Glossary abbreviations

Building leadership in solid tumors with lifecycle management

As of: October 22, 2026

	Phase 1	Phase 2	Phase 3	Approved[1]
Breast/ Gynecologic cancers				**Baituowei (Goserelin)** Breast, Prostate
Gastro-intestinal		**BGB-A317-216** **Tislelizumab PD-1 mAb** 1L ESCC (JP)	**JZP598-302[2]** **Zanidatamab HER2 bsAb** 1L BTC[3]	**ZWI-ZW25-301[2]** **Zanidatamab HER2 bsAb** 1L HER2+ GEA **BGB-A317-302** **Tislelizumab PD-1 mAb** 2L ESCC **ZWI-ZW25-203[2]** **Zanidatamab HER2 bsAb** HER2+ 2L+ BTC (CN)[4] **BGB-A317-305** **Tislelizumab PD-1 mAb** 1L GC **BGB-A317-208** **Tislelizumab PD-1 mAb** 2L/3L + HCC **BGB-A317-306** **Tislelizumab PD-1 mAb** 1L ESCC **BGB-A317-301** **Tislelizumab PD-1 mAb** 1L HCC
Lung				**BGB-A317-303** **Tislelizumab PD-1 mAb** 2/3L NSCLC **BGB-A317-312** **Tislelizumab PD-1 mAb** 1L ES-SCLC **BGB-A317-304** **Tislelizumab PD-1 mAb** 1L Non-sq. NSCLC **BGB-A317-315** **Tislelizumab PD-1 mAb** Neo/adj. NSCLC **BGB-A317-307** **Tislelizumab PD-1 mAb** 1L Sq. NSCLC **BGB-A317-309** **Tislelizumab PD-1 mAb** 1L NPC
Other			**BGB-A317-316** **Tislelizumab PD-1 mAb** SubQ formulation **BGB-A317-310** **Tislelizumab PD-1 mAb** 1L UC	**BGB-A317-204** **Tislelizumab PD-1 mAb** 2L UBC **BGB-A317-209** **Tislelizumab PD-1 mAb** Late Line MSI-H or dMMR (CN)[4]
I&I	**BGB-16673-107** **Tacabrutideg BTK CDAC** Chronic Spontaneous Urticaria **BG-A3004-101** **KLRG1 mAb** I&I (CN)		**BGB-3111-309** **Zanubrutinib BTKi** PMN	

[1] Approved in at least one major market, such as U.S., CN, EU, and/or JP
[2] Zymeworks/Jazz collaboration
[3] Confirmatory trial for ZWI-ZW25-203 2L+ BTC
[4] Conditional approval

Refer to Glossary abbreviation
Studies in "close-out" status excluded

Global clinical development pipeline

As of: November 4, 2026

Phase 1

Sonrotoclax — BCL2i
- 101 B-cell malignancies
- 103 MDS
- 105 R/R MM t(11;14)
- 109 B-cell malig. pediatric**

Tacabrutideg — BTK CDAC
- 101/102 B-cell malignancies
- 104 B-cell malignancies
- 107 Chr. spontaneous urticaria

BG-T0050 — CD19xCD20xCD3 tsAb
- 101 B-cell malignancies**

BG-T0920 — BAFFRxCD22xCD3 tsAb
- 101 B-cell malignancies**

BG-C9074[1] — B7-H4 ADC
- 101 Solid tumors

BGB-21447 — BCL2i
- 101 Solid tumors

BG-75098 — CDK2 CDAC
- 101 Solid tumors

BGB-43395 — CDK4i
- 101 Solid tumors

BGB-B455 — CLDN6 x CD3 bsAb
- 101 Solid tumors

BG-75202 — KAT6A/Bi
- 101 Solid tumors
- 102 Myeloid malignancies

BG-C0979 — ADAM9 ADC
- 101 Solid tumors

BON-C1393 — B7-H3xITGB6 bsADC
- 101 Solid tumors**

BG-C477 — CEA ADC
- 101 Solid tumors

BG-T187 — EGFRxMETxMET tsAb
- 101 Solid tumors

BG-C0902 — EGFRxMETxMET tsADC
- 101 Solid tumors

BGB-58067 — MTA Coop. PRMT5i
- 101 Solid tumors

Tarlatamab[2] — DLL3 x CD3 BiTE®
- DeLLphi-308 2L+ SCLC SubQ
- DeLLphi-310 2L+ SCLC (+B7-H3)

BG-92505 — KEAP1 activator
- 101 Solid tumors**

BON-110[3] — PD1xVEGFxCTLA4 tsAb
- 101 Solid tumors

BON-106 — *Target not disclosed*
- 101 Solid tumors**

BG-85738 — RAS(ON)i
- 101 Solid tumors

BGB-B2033 — GPC3 x 4-1BB bsAb
- 101 Solid tumors

BGB-26808 — HPK1i
- 101 Solid tumors

Xaluritamig[2] — STEAP1xCD3 BiTE®
- 20180146 mCRPC

BG-A3004 — KLRG1 mAb
- 101 Immunology and Inflammation

BGB-45035 — IRAK4 CDAC
- 101 Immunology and Inflammation

Phase 2

Sonrotoclax — BCL2i
- 103 AML
- 108 Dose ramp-up
- 203 R/R WM

Tacabrutideg — BTK CDAC
- 101 R/R CLL
- 101 R/R WM
- 102 R/R CLL
- 302 R/R CLL

Blinatumomab[2] — CD19 x CD3 BiTE®
- 20180257 R/R B-ALL SubQ, MRD+

BGB-B2033 — GPC3 x 4-1BB bsAb
- 101 3L+ HCC

BGB-B2033 — GPC3 x 4-1BB bsAb
- 201 2L+ HCC**

Tislelizumab — PD-1 mAb
- 216 1L ESCC (Q2W/Q4W)

Tarlatamab[2] — DLL3 x CD3 BiTE®
- DeLLphi-309 2L SCLC alt dosing

Phase 3

Zanubrutinib — BTKi
- 306 TN MCL
- 308 R/R MZL, R/R FL
- 309 pMN

Sonrotoclax — BCL2i
- 301 TN CLL
- 302 R/R MCL
- 303 R/R CLL
- 304 TN CLL (vs. AV)

Tacabrutideg — BTK CDAC
- 303 R/R CLL
- 304 R/R CLL (vs. Pirto)

BGB-43395 — CDK4i
- 302 1L HR+/HER2- BC

BG-C9074 — B7-H4 ADC
- 301 1L Maintenance OC

Tarlatamab[2] — DLL3 x CD3 BiTE®
- DeLLphi-305 1L ES-SCLC MTx
- DeLLphi-306 LS-SCLC
- DeLLphi-312 1L ES-SCLC Ind+MTx
- DeLLphi-315 2L ES-SCLC SubQ

Zanidatamab[4] — HER2 bsAb
- 302 1L BTC

BGB-B2033 — GPC3 x 4-1BB bsAb
- 301 2L+ HCC**

Tislelizumab — PD-1 mAb
- 310 1L UC
- 316 SubQ

Accepted submissions

Major markets (U.S., CN, EU, JP)

Sonrotoclax — BCL2i
- 201 R/R MCL (EU)

Zanubrutinib — BTKi
- 114 Tablet formulation (JP)
- 214 R/R MZL (JP)
- 306 TN MCL (CN, U.S.)

Tislelizumab — PD-1 mAb
- ZW25-301 1L HER2+ GEA (CN)

Zanidatamab[4] — HER2 bsAb
- ZW25-301 1L HER2+ GEA (CN)

- Hematology
- Lung
- Breast / Gynecological
- Gastrointestinal
- Other cancers
- Immunology and Inflammation

[1] DualityBio collaboration
[2] Amgen collaboration
[3] Huahui Health collaboration
[4] Zymeworks/Jazz collaboration

**Trial is listed on CT.gov but may not have any subjects enrolled

Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details

I&I portfolio

As of: 22 Oct 2026

	Phase 1	Phase 2	Phase 3
I&I	**BG-A3004-101** **KLRG1 mAb** I&I (CN) **BGB-16673-107** **Tacabrutideg BTK CDAC** Chronic Spontaneous Urticaria		**BGB-3111-309** **Zanubrutinib BTKi** PMN

Studies in “close-out” status excluded
Refer to Glossary abbreviation

Trial detail

- **BRUKINSA®** (zanubrutinib)
- **BEQALZI™** (sonrotoclax)
- **Tacabrutideg**
- **Other hematology assets**
- **TEVIMBRA®** (tislelizumab)
- **Other solid tumor assets**
- **Immunology and inflammation assets**

BRUKINSA® (zanubrutinib)
Foundational asset in hematology portfolio

As of: October 22, 2026

Trial	Phase	CT.gov	Population	Total patients[1]	Combination molecule(s)	Primary endpoint(s)	Status
BGB-3111-304 (SEQUOIA)	**Phase 3**	NCT03336333	TN CLL/SLL	784	Venetoclax (arm D)	PFS	Approved[2] / Maint. (arm D)
BGB-3111-306 (MANGROVE)	**Phase 3**	NCT04002297	TN MCL	510	Rituximab	PFS	Maintenance
BGB-3111-308 (MAHOGANY)	**Phase 3**	NCT05100862	R/R MZL and FL	799	Rituximab, Obinutuzumab	PFS	Maintenance
BGB-3111-LTE1	**Phase 3**	NCT04170283	B-cell malignancies	956		TEAEs	Maintenance
BGB-3111-114	**Phase 1**	NCT05767398	Healthy volunteers	58	-	PK	Approved[2]
BGB-3111-206	**Phase 2**	NCT03206970	R/R MCL	86	-	ORR	Approved[2]
BGB-3111-212 (ROSEWOOD)	**Phase 2**	NCT03332017	R/R FL	217	Obinutuzumab	ORR	Approved[2]
BGB-3111-214 (MAGNOLIA)	**Phase 2**	NCT03846427	R/R MZL	68	-	ORR	Approved[2]
BGB-3111-302 (ASPEN)	**Phase 3**	NCT03053440	TN and R/R WM	229	-	CR\VGPR	Approved[2]
BGB-3111-305 (ALPINE)	**Phase 3**	NCT03734016	R/R CLL	652	-	ORR	Approved[2]

[1] Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2] Approved in at least one major market, such as the U.S., EU, China and/or Japan
Refer to Glossary abbreviations

Brukinsa® zanubrutinib

BEQALZI™ (sonrotoclax)

Potential best-in-class BCL2 inhibitor with differentiated profile

As of: October 22, 2026

Trial	Phase	CT.gov	Population	Total patients[1]	Combination molecule(s)	Primary endpoint(s)	Status
BGB-11417-101	**Phase 1**	NCT04277637	B-cell malignancies and NHL	437	Zanubrutinib, Obinutuzumab	TEAEs, MTD	Maintenance
BGB-11417-103	**Phase 1/2**	NCT04771130	AML/MDS	260	Azacitidine	TEAEs, CR, mOR	Enrolling
BGB-11417-105	**Phase 1/2**	NCT04973605	R/R MM with t(11;14)	246	Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide	TEAEs, ORR, VGPR, CR	Enrolling
BGB-11417-108	**Phase 1/2**	NCT06697184	B-cell malignancies	258	Zanubrutinib	TLS	Enrolling
BGB-11417-109[2]	**Phase 1/2**	NCT07770698	Pediatric AML/ALL	30	Azacitidine, Inotuzumab Ozogamicin + Dexamethasone	TEAEs, RDFE	Enrolling
BGB-11417-203	**Phase 2**	NCT05952037	R/R WM	114	Zanubrutinib	MRR	Maintenance
BGB-11417-204	**Phase 2**	NCT06637501	TN CLL	94	Zanubrutinib	CR/CRi	Maintenance
BGB-11417-301 (CELESTIAL-TNCLL)	**Phase 3**	NCT06073821	TN CLL/SLL (+Zanu)	711	Zanubrutinib	PFS	Maintenance
BGB-11417-302 (CELESTIAL-RRMCL)	**Phase 3**	NCT06742996	R/R MCL	300	Zanubrutinib	PFS	Enrolling
BGB-11417-303 (CELESTIAL-RRCLL)	**Phase 3**	NCT06943872	R/R CLL/SLL	630	Obinutuzumab, Rituximab	PFS	Enrolling
BGB-11417-304 (CELESTIAL-TNCLL2)	**Phase 3**	NCT07277231	TN CLL (vs. acala + ven)	500	Zanubrutinib	PFS	Enrolling
BGB-11417-201	**Phase 2**	NCT05471843	R/R MCL	124	-	TEAEs, ORR	Approved in CN and U.S.; Maint. ROW
BGB-11417-202	**Phase 2**	NCT05479994	R/R CLL	100	-	ORR	Approved[3]

[1] Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2] Trial is listed on CT.gov but may not have any subjects enrolled
[3] Approved in at least one major market, such as the U.S., EU, China and/or Japan
Refer to Glossary abbreviations

BEQALZI™ (sonrotoclax)

Tacabrutideg

Potential first-in-class and best-in-class BTK degrader

As of: October 22, 2026

Trial	Phase	CT.gov	Population	Total patients[1]	Combination molecule(s)	Primary endpoint(s)	Status
BGB-16673-101 (CaDAnCe-101)	**Phase 1/2**	NCT05006716	B-cell malignancies	689	-	TEAEs	Enrolling
BGB-16673-102 (CaDAnCe-102)	**Phase 1/2**	NCT05294731	B-cell malignancies (CN)	146	-	TEAEs, RP2D, ORR	Enrolling
BGB-16673-104 (CaDAnCe-104)	**Phase 1/2**	NCT06634589	B-cell malignancies	80	Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab	DLTs, TEAEs	Enrolling
BGB-16673-302 (CaDAnCe-302)	**Phase 2**	NCT06846671	R/R CLL/SLL (vs. investigators choice)	250	-	PFS	Enrolling
BGB-16673-303 (CaDAnCe-303)	**Phase 3**	NCT06970743	R/R CLL/SLL (CN)	152	-	PFS	Maintenance
BGB-16673-304 (CaDAnCe-304)	**Phase 3**	NCT06973187	R/R CLL/SLL (vs. pirtobrutinib)	500	-	PFS	Enrolling

[1] Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
Refer to Glossary abbreviations

Phase 1 and 2 – other hematology assets

As of: October 22, 2026

Trial	MOA	Phase	CT.gov	Population	Total patients[1]	Combination molecule(s)	Primary endpoint(s)	Status
BG-T0920-101[2]	BAFFRxCD22xCD3 tsAb	**Phase 1**	NCT07887646	DLBCL and B-cell malignancies	70	-	DLTs, TEAEs, TRAEs, SAEs	Enrolling
BG-T0050-101[2]	CD19xCD20xCD3 tsAb	**Phase 1**	NCT07881211	DLBCL and B-cell malignancies	70	-	DLTs, TEAEs, TRAEs, SAEs	Enrolling
BG-75202-102	KAT6A/Bi	**Phase 1**	NCT07619287	Myeloid malignancies	118	Hypomethylation agent	AEs, RDFE, CR/CRh	Enrolling
BLINCYTO® 20180257	CD19 x CD3 BiTE®	**Phase 2**	NCT04521231	R/R and MRD+ B-ALL (SubQ)	181[3]	-	CR/CRh, CR, MRD	Maintenance
BLINCYTO® 20190359[4]	CD19 x CD3 BiTE®	**Phase 2**	NCT06054113	Pediatric R/R B-ALL (cIV)	18[3]	-	CR/CRh	Maintenance

[1] Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2] Trial is listed on CT.gov but may not have any subjects enrolled
[3] Total planned enrollment, with BeOne territories included
[4] Post approval commitment
Refer to Glossary abbreviations

TEVIMBRA® (tislelizumab)
Poised for global patient impact

As of: October 22, 2026

Trial	Phase	CT.gov	Population	Total patients[1]	Combination molecule(s)	Primary endpoint(s)	Status
BGB-LC-201	**Phase 2**	NCT05635708	1L NSCLC	418	LAG3, OX40, HPK1, Chemotherapy	ORR	Closeout
BGB-A317-216	**Phase 2**	NCT07733180	1L ESCC	30	Chemotherapy	AEs, SAEs, ORR	Enrolling
BGB-A317-217	**Phase 2**	NCT07554521	1L GC and ESCC	30	Chemotherapy	AEs, SAEs	Enrolling
BGB-A317-316	**Phase 3**	NCT07043400	SubQ formulation	351	Chemotherapy	PK	Enrolling
BGB-A317-310 (RATIONALE-310)	**Phase 3**	NCT04004221	1L UC	420	Chemotherapy	OS (ITT)	Maintenance
BGB-A317-204	**Phase 2**	NCT03967977	2L UBC	113	-	ORR	Approved[2]
BGB-A317-312 (RATIONALE-312)	**Phase 3**	NCT04005716	1L ES-SCLC	457	Chemotherapy	OS	Approved[3]
BGB-A317-315 (RATIONALE-315)	**Phase 3**	NCT04379635	Neo/adj NSCLC	453	Chemotherapy	MPR, EFS	Approved[3]

[1] Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2] Approved only in China
[3] Approved in at least one major market, such as the U.S., EU, China and/or Japan
Refer to Glossary abbreviations

TEVIMBRA (tislelizumab)

TEVIMBRA® (tislelizumab)
Poised for global patient impact

As of: October 22, 2026

Trial	Phase	CT.gov	Population	Total patients[1]	Combination molecule(s)	Primary endpoint(s)	Status
BGB-A317-208	**Phase 2**	NCT03419897	2L+ HCC	249	-	ORR	Approved[2]
BGB-A317-209	**Phase 2**	NCT03736889	Late line MSI-H or dMMR solid tumors	150	-	ORR	Approved[2]
BGB-A317-301 (RATIONALE-301)	**Phase 3**	NCT03412773	1L HCC	684	-	OS	Approved[3]
BGB-A317-302 (RATIONALE-302)	**Phase 3**	NCT03430843	2L ESCC	513	-	OS	Approved[3]
BGB-A317-303 (RATIONALE-303)	**Phase 3**	NCT03358875	2/3L NSCLC	805	-	OS (PDL1+), OS	Approved[3]
BGB-A317-304 (RATIONALE-304)	**Phase 3**	NCT03663205	1L Non-sq. NSCLC	334	Chemotherapy	PFS	Approved[3]
BGB-A317-305 (RATIONALE-305)	**Phase 3**	NCT03777657	1L GC	997	Chemotherapy	OS	Approved[3]
BGB-A317-306 (RATIONALE-306)	**Phase 3**	NCT03783442	1L ESCC	649	Chemotherapy	OS	Approved[3]
BGB-A317-307 (RATIONALE-307)	**Phase 3**	NCT03594747	1L Sq. NSCLC	360	Chemotherapy	PFS	Approved[3]
BGB-A317-309 (RATIONALE-309)	**Phase 3**	NCT03924986	1L NPC	263	Chemotherapy	PFS	Approved[3]

[1] Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2] Approved only in China
[3] Approved in at least one major market, such as the U.S., EU, China and/or Japan
Refer to Glossary abbreviations

TEVIMBRA (tislelizumab)

Phase 1 – other solid tumor assets

As of: October 22, 2026

Trial	Asset	MOA	Phase	CT.gov	Population	Total patients[1]	Combination molecule(s)	Primary endpoint(s)	Status
BGB-21447-102	BGB-21447	BCL2i	**Phase 1**	NCT06756932	2L+ HR+/HER2- BC	120	BGB-43395 ± fulvestrant	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BG-75098-101	BG-75098	CDK2 CDAC	**Phase 1**	NCT07226349	Solid Tumors	105	BGB-43395, Fulvestrant	AE, SAE, RDFE, ORR	Dose Escalation
BGB-B455-101	BGB-B455	Claudin 6 x CD3 bsAb	**Phase 1**	NCT06803680	Solid Tumors	90	-	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BG-75202-101	BG-75202	KAT6A/Bi	**Phase 1**	NCT07222267	Solid Tumors	86	Estrogen receptor antagonist, CDK4i, aromatase inhibitor	AE, SAE, MTD, RDFE, ORR	Dose Escalation
BG-C0979-101	BG-C0979	ADAM9 ADC	**Phase 1**	NCT07414836	Solid Tumors	84	Tislelizumab	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BG-C0902-101	BG-C0902	EGFR x MET x MET tsADC	**Phase 1**	NCT07181681	Solid Tumors	63	-	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BON-110-101[2]	BON-110	PD-1 x VEGFA x CTLA4 tsAb	**Phase 1**	NCT07623369	Solid Tumors	299	-	SAE, TEAE, DLT, MTD	Dose Escalation
BON-106-101[3]	BON-106	*Target not disclosed*	**Phase 1**	NCT07893535	Solid Tumors	70	-	SAE, TEAE, DLT	Dose Escalation
BG-92505-101[3]	BG-92505	KEAP1 activator	**Phase 1**	NCT07896460	Solid Tumors	137	± anti-cancer agents	SAE, TEAE, DLT	Dose Escalation
BON-C1393-101[3]	BON-C1393	B7-H3 x ITGB6 bsADC	**Phase 1**	NCT07904845	Solid Tumors	90	± bevacizumab, capecitabine	SAE, TEAE, DLT, ORR	Dose Escalation
BG-85738-101	BG-85738	RAS(ON)i	**Phase 1**	NCT07746141	Solid Tumors	100	BG-85738 ± tislelizumab or cetuximab	AE, SAE, DLT, MTD, RDFE, ORR, RP2D	Dose Escalation

1 Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
2 BON-110 also known as HH-160
3 Trial is listed on CT.gov but may not have any subjects enrolled
Refer to Glossary abbreviations

Phase 1 – other solid tumor assets

As of: October 22, 2026

Trial	Asset	MOA	Phase	CT.gov	Population	Total patients[1]	Combination molecule(s)	Primary endpoint(s)	Status
BGB-43395-101	BGB-43395	CDK4i	**Phase 1**	NCT06120283	BC and Solid Tumors	433	Fulvestrant, Letrozole	AE, SAE, DLT, MTD, RDFE, ORR	Dose Expansion
BG-C477-101	BG-C477	CEA ADC	**Phase 1**	NCT06596473	Solid Tumors	310	Chemotherapy	AE, SAE, DLT, MTD, RDFE, ORR	Dose Expansion
BG-C9074-101	BG-C9074	B7-H4 ADC	**Phase 1**	NCT06233942	Solid Tumors	308	Tislelizumab	TEAE, SAE, DLT, MTD, RDFE, ORR, RP2D	Dose Expansion
BGB-B2033-101	BGB-B2033	GPC3 x 4-1BB bsAb	**Phase 1/2**	NCT06427941	Solid Tumors	630	Tislelizumab	AE, SAE, DLT, MTD, RP2D	Dose Expansion
BGB-58067-101	BGB-58067	PRMT5i	**Phase 1**	NCT06589596	Solid Tumors	525	-	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Expansion
BGB-A317-26808-101	BGB-26808	HPK1i	**Phase 1**	NCT05981703	Solid Tumors	337	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Dose Expansion
BG-T187-101	BG-T187	EGFR x MET x MET tsAb	**Phase 1**	NCT06598800	Solid Tumors	153	-	AE, SAE, DLT, MTD, RDFE, ORR	Dose Expansion
AMG 757 20230298 (DeLLphi-308)	Tarlatamab	DLL3 x CD3 BiTE® (SubQ)	**Phase 1**	NCT06598306	2L+ SCLC	220[2]	-	DLTs, SAEs, TEAEs	Enrolling
AMG 509 20180146	Xaluritamig	STEAP1 x CD3 BiTE®	**Phase 1**	NCT04221542	mCRPC	479[2]	-	TEAEs, DLTs	Enrolling
AMG 757 20240124 (DeLLphi-310)	Tarlatamab	DLL3 x CD3 BiTE® (+B7-H3 ADC)	**Phase 1**	NCT06898957	2L+ SCLC	29[2]	YL201	DLTs, TEAEs	Maintenance
BG-68501-101	BG-68501	CDK2i	**Phase 1**	NCT06257264	Solid Tumors	103	BGB-43395, Fulvestrant	AE, SAE, DLT, MTD, RDFE, ORR	Closeout
BG-C137-101	BG-C137	FGFR2b ADC	**Phase 1**	NCT06625593	Solid Tumors	168	-	AE, SAE, DLT, MTD, RDFE, ORR	Closeout

[1] Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2] Total planned enrollment, with BeOne territories included
Refer to Glossary abbreviations

Phase 2 – other solid tumor assets

As of: October 22, 2026

Trial	Asset	MOA	Phase	CT.gov	Population	Total patients[1]	Combination molecule(s)	Primary endpoint(s)	Status
BGB-B2033-201[2] (GroundBBreaker-201)	BGB-B2033	GPC3 x 4-1BB bsAb	**Phase 2**	NCT07911683	2L+ HCC	100	-	ORR	Enrolling
AMG 757 20240092 (DeLLphi-309) (Alt dosing)	Tarlatamab	DLL3 x CD3 BiTE®	**Phase 2**	NCT06745323	2L SCLC	252[3]	-	ORR	Maintenance
BGB-A317-A445-201	BGB-A445	OX40 mAb	**Phase 2**	NCT05661955	Melanoma, UC	113	Tislelizumab	ORR	Closeout
BGB-LBL-007-201	BGB-LBL-007	LAG3 mAb	**Phase 2**	NCT05609370	MSS-CRC	113	Tislelizumab, Chemotherapy, Bevacizumab	PFS, AE, SAE	Closeout
AMG 757 20230273 (DeLLphi-307)	Tarlatamab	DLL3 x CD3 BiTE®	**Phase 2**	NCT06502977	3L+ ES-SCLC	32 (CN)[3]	-	ORR	Approved[4]
ZWI-ZW25-203 (HERIZON-BTC-01)	Zanidatamab	HER2 bsAb	**Phase 2**	NCT04466891	2L+ BTC	55[5]	-	ORR	Approved[4]

1 Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
2 Trial is listed on CT.gov but may not have any subjects enrolled
3 Planned enrollment. BeOne territories included
4 Approved only in China
5 BeOne territories only
Refer to Glossary abbreviations

Phase 3 – other solid tumor assets

As of: October 22, 2026

Trial	Asset	MOA	Phase	CT.gov	Population	Total patients[1]	Combination molecule(s)	Primary endpoint(s)	Status
BGB-B2033-301[2] (GroundBBreaker-301)	BGB-B2033	GPC3 x 4-1BB bsAb	**Phase 3**	NCT07836530	2L+ HCC	492	-	OS	Enrolling
BG-C9074-301 (Starstone-301)	BG-C9074	B7-H4 ADC	**Phase 3**	NCT07811271	1L MTx OC	600	+ Bevacizumab	PFS	Enrolling
BGB-43395-302 (KANDELA-302)	BGB-43395	CDK4i	**Phase 3**	NCT07492641	1L HR+/HER2- BC	1056	Letrozole	PFS	Enrolling
JZP598-302 (HERIZON-BTC-302)	Zanidatamab	HER2 bsAb	**Phase 3**	NCT06282575	1L BTC	286[3]	Chemo ± Pembrolizumab/Durvalumab	PFS	Enrolling
AMG 757 20250046 (DeLLphi-315) (SubQ vs. IV)	Tarlatamab	DLL3 x CD3 BiTE®	**Phase 3**	NCT07778316	2L ES-SCLC	400[4]	-		Enrolling
AMG 757 20200041 (DeLLphi-305) (Maintenance)	Tarlatamab	DLL3 x CD3 BiTE®	**Phase 3**	NCT06211036	1L ES-SCLC	563[4]	Durvalumab (maintenance)	OS	Maintenance
AMG 757 20230016 (DeLLphi-306)	Tarlatamab	DLL3 x CD3 BiTE®	**Phase 3**	NCT06117774	LS-SCLC	404[4]	-	PFS, OS	Maintenance
AMG 757 20240178 (DeLLphi-312) (Induction + Maintenance)	Tarlatamab	DLL3 x CD3 BiTE®	**Phase 3**	NCT07005128	1L ES-SCLC	350[4]	Durvalumab +chemo (induction); Durvalumab (maintenance)	PFS, OS	Maintenance
ZWI-ZW25-301 (HERIZON-GEA-01)	Zanidatamab	HER2 bsAb	**Phase 3**	NCT05152147	1L HER2+ GEA	437[5]	Chemo ± Tislelizumab	PFS, OS	Approved
AMG 757 20210004 (DeLLphi-304)	Tarlatamab	DLL3 x CD3 BiTE®	**Phase 3**	NCT05740566	2L SCLC	509[4]	-	OS	Approved

[1] Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2] Trial is listed on CT.gov but may not have any subjects enrolled
[3] BeOne responsible for CN enrollment
[4] Total planned enrollment, with BeOne territories included
[5] BeOne territories only
Refer to Glossary abbreviations

Immunology and inflammation assets

As of: October 22, 2026

Trial	MOA	Phase	CT.gov	Population	Total patients[1]	Combination molecule(s)	Primary endpoint(s)	Status
BG-A3004-101	KLRG1 mAb	**Phase 1**	NCT07412691	Healthy participants and patients with immune-mediated skin diseases	98	-	Incidence and severity of TEAEs and SAEs	Enrolling
BGB-16673-107	BTK CDAC	**Phase 1**	NCT07005713	Chronic spontaneous urticaria (CSU)	58	-	Incidence and severity of TEAEs	Enrolling
BGB-3111-309 (ALMOND)	BTKi	**Phase 2/3**	NCT05707377	Primary Membranous Nephropathy	178	-	Urine Protein Creatinine Ratio, Complete Remission	Maintenance

[1] Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
Refer to Glossary abbreviations

Full list of commercial and clinical assets

As of: October 22, 2026

Commercial

Product	Commercial rights	Partner
BRUKINSA® (zanubrutinib)	Global	-
TEVIMBRA® (tislelizumab)	Global	-
BEQALZI™ (sonrotoclax)[1]	Global	-
IMDELLTRA® (tarlatamab)[2]	China	Amgen
XGEVA® (denosumab)	China	Amgen
BLINCYTO® (blinatumomab)	China	Amgen
KYPROLIS® (carfilzomib)	China	Amgen
ZIIHERA® (zanidatamab)	APAC[3]	Zymeworks /Jazz
SYLVANT® (siltuximab)	China	Recordati
QARZIBA® (dinutuximab)	China	Recordati
TAFINLAR® (dabrafenib)	China	Novartis
MEKINIST® (trametinib)	China	Novartis
VOTRIENT® (pazopanib)	China	Novartis
AFINITOR® (everolimus)	China	Novartis
ZYKADIA® (ceritinib)	China	Novartis
POBEVCY® (Avastin biosimilar)	China	Bio-Thera
BAITUOWEI® (goserelin microspheres for injection)	China	Luye Pharma

Pipeline

Asset	Latest stage	Partner	Asset	Latest stage	Partner
BGB-16673 (tacabrutideg)	Ph3	-	**BG-92505** (KEAP1 activator)	Ph1	-
BGB-43395 (CDK4i)	Ph3	-	**BON-110** (PD-1 x VEGFA x CTLA4 tsAb)	Ph1	Huahui Health
BGB-B2033 (GPC3 x 4-1BB bsAb)	Ph3	-	**BON-106** (*Target not disclosed*)	Ph1	-
BG-C9074 (B7-H4 ADC)	Ph3	Duality Bio	**BG-85738** (RAS(ON)i)	Ph1	-
BGB-58067 (MTA Coop. PRMT5i)	Ph1	-	**BGB-26808** (HPK1i)	Ph1	
BG-C477 (CEA ADC)	Ph1	-	**Xaluritamig** (STEAP1 x CD3 BiTE®)[5]	Ph1	Amgen
BG-71332 (zanu + sonro)[4]	Ph1	-	**BG-A3004** (KLRG1 mAb)	Ph1	-
BG-T0920 (BAFFR x CD22 x CD3 tsAb)	Ph1	-	**BGB-45035** (IRAK4 CDAC)	Ph1	-
BG-T0050 (CD19 x CD20 x CD3 tsAb)	Ph1	-			
BGB-21447 (BCL2i)	Ph1	-			
BG-75098 (CDK2 CDAC)	Ph1	-			
BGB-B455 (Claudin 6 x CD3 bsAb)	Ph1	-			
BG-75202 (KAT6A/Bi)	Ph1	-			
BG-C0979 (ADAM9 ADC)	Ph1	-			
BON-C1393 (B7-H3 x ITGB6 bsADC)	Ph1	-			
BG-T187 (EGFR x MET x MET tsAb)	Ph1	-			
BG-C0902 (EGFR x MET x MET tsADC)	Ph1	-			

1 Beqalzi is currently approved in U.S. for R/R MCL and in China for R/R MCL and R/R CLL
2 Amgen collaboration. A significant portion of our rights to receive certain tiered mid-single digit royalty payments based on annual net revenue from sales outside of China of IMDELLTRA were sold to Royalty Pharma in the third quarter of 2025
3 Excluding Japan and India
4 Further clinical development activities planned
5 Study is being conducted in China as part of the BeOne-Amgen collaboration
Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details

Glossary

As of: October 22, 2026

Disease abbreviations

AD	Atopic dermatitis	**MM**	Multiple myeloma
AML	Acute myeloid leukemia	**MSI-H**	Microsatellite instability high
BP-ALL	B-precursor acute lymphocytic leukemia	**MSS CRC**	Microsatellite stable colorectal cancer
BTC	Biliary tract cancer	**MZL**	Marginal zone lymphoma
CLL	Chronic lymphocytic leukemia	**NSCLC**	Non-small cell lung cancer
CSU	Chronic spontaneous urticaria	**NPC**	Nasopharyngeal carcinoma
DLBCL	Diffuse Large B-Cell Lymphoma	**PMN**	Primary membranous nephropathy
dMMR	Deficient DNA mismatch repair	**PN**	Prurigo nodularis
ES-SCLC	Extensive stage small cell lung cancer	**PSR OC**	Platinum sensitive recurrent ovarian cancer
ESCC	Esophageal squamous cell carcinoma	**R/R**	Relapsed or refractory
FL	Follicular lymphoma	**SCLC**	Small cell lung cancer
GEA	Gastroesophageal adenocarcinoma	**SLL**	Small lymphocytic lymphoma
GC	Gastric cancer	**UC / UBC**	Urinary / bladder cancer
HCC	Hepatocellular carcinoma	**WM**	Waldenström's macroglobulinemia
HNSCC	Head and neck squamous cell carcinoma		
LS-SCLC	Limited stage small cell lung cancer		
MCL	Mantle cell lymphoma		
mCRPC	Metastatic castration resistant prostate cancer		
MDS	Myelodysplastic syndromes		

Other abbreviations

ADC	Antibody drug conjugate	**MPR**	Major pathological response
AE	Adverse event	**MRD**	Minimal residual disease
bsAb	Bi-specific antibody	**MTD**	Maximum tolerated dose
bsADC	Bi-specific antibody drug conjugate	**MTx**	Maintenance
BiTE®	Bi-specific T-cell engager	**NME**	New molecular entity
CDAC	Chimeric degradation activation compound	**ORR**	Objective response rate
CR	Complete response	**OS**	Overall survival
CRh	Complete remission with partial hematological recovery	**PCR**	Pathologic complete response
DCR	Disease control rate	**PFS**	Progression-free survival
DLT	Dose-limiting toxicity	**RDFE**	Recommended dose for expansion
DOR	Duration of response	**RP2D**	Recommended Phase 2 dose
EFS	Event free survival	**SAE**	Serious adverse event
HV	Healthy volunteers	**TEAE**	Treatment emergent adverse event
IITs	Investigator-Initiated Trials	**TN**	Treatment naïve
LCM	Lifecycle management	**tsAb**	Tri-specific antibody
LTE	Long-term extension	**tsADC**	Tri-specific antibody drug conjugate
mAb	Monoclonal antibody	**VGPR**	Very good partial response
mOR	Modified overall response		